Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer ...
(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...
Erasca (ERAS) on Monday announced a clinical trial collaboration and supply agreement (CTCSA) with Merck (MRK), known as MSD ...
New cancer trial: Merck and Erasca will test ERAS-0015 with Keytruda in RAS-mutant solid tumors under the AURORAS-1 study. Potential treatment boost: The combination targets tumor pathways and immune ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue [NRAS], ...
Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown ...
When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS ...
Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease Targeted inhibition using small molecule inhibitors works in smoking-related lung cancer. Responses with ...
Erasca, Inc. (NASDAQ:ERAS) is one of the best performing healthcare stocks so far in 2026. The Fly reported on May 4 that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results